

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1548)

**VOLUNTARY ANNOUNCEMENT
RESEARCH AND DEVELOPMENT UPDATE**

This announcement is made by Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group. References are made to the announcements of the Company dated March 13, 2018, August 6, 2020 and January 2, 2023.

The board of directors (the “**Board**”) of the Company is pleased to announce that on August 27, 2024, the National Medical Products Administration of China (the “**NMPA**”) has announced the approval of the New Drug Application (NDA) for ciltacabtagene autoleucel (cilta-cel) made by Nanjing Legend Biotech Co., Ltd., an indirect non-wholly owned subsidiary of the Company, for the treatment of eligible adult patients with relapsed or refractory multiple myeloma as defined in the prescribing information of cilta-cel.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, August 27, 2024

As at the date of this announcement, the executive Directors are Dr. Fangliang Zhang, Mr. Jiange Meng, Ms. Ye Wang and Dr. Li Zhu; the non-executive Director is Dr. Luquan Wang; and the Independent non-executive Directors are Mr. Zumian Dai, Mr. Jiuan Pan, Mr. Yiu Leung Andy Cheung and Dr. Chenyang Shi.